International Clinical Trial: Transformative Study of Orelabrutinib Combined with Pola-R-CHP Regimen in the First-Line Treatment of Patients with Intermediate-High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134152) titled 'Transformative Study of Orelabrutinib Combined with Pola-R-CHP Regimen in the First-Line Treatment of Patients with Intermediate-High Risk Diffuse Large B-Cell Lymphoma (DLBCL)' on Oct. 11.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of Xiamen University

Condition: First-line intermediate-high risk DLBCL

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2025-12-01

Target Sample Size: Experimental group:30;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=299023

Publish...